Charles River Laboratories International, Inc. $CRL Stock Position Lifted by Magnetar Financial LLC

Magnetar Financial LLC raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,379.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,173 shares of the medical research company’s stock after buying an additional 21,607 shares during the quarter. Magnetar Financial LLC’s holdings in Charles River Laboratories International were worth $3,626,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its stake in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after acquiring an additional 1,074 shares during the last quarter. Empowered Funds LLC acquired a new stake in Charles River Laboratories International during the first quarter valued at $418,000. Fox Run Management L.L.C. purchased a new position in Charles River Laboratories International in the second quarter valued at about $400,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Charles River Laboratories International by 2.7% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,943 shares of the medical research company’s stock valued at $8,488,000 after purchasing an additional 1,486 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Charles River Laboratories International in the 2nd quarter worth about $803,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, December 15th. Citigroup increased their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a research report on Monday, December 1st. Barclays reduced their target price on shares of Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, February 19th. Finally, TD Cowen decreased their target price on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Ten equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $203.57.

Charles River Laboratories International Stock Up 0.9%

Charles River Laboratories International stock opened at $168.88 on Thursday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. The firm has a market cap of $8.31 billion, a price-to-earnings ratio of -57.05, a P/E/G ratio of 2.86 and a beta of 1.64. The firm has a fifty day moving average price of $193.48 and a two-hundred day moving average price of $181.14.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. During the same quarter in the prior year, the company earned $2.66 EPS. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.